However, plasma ALT and AST concentrations are still regarded as better clinical indicators than other noninvasive biomarkers/scores for definitive diagnosis of nonalcoholic steatohepatitis (NASH) and/or advanced fibrosis in patients with T2DM [25]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.